Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Seibyl

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
Journal of Parkinson'S Disease|July 16, 2019
The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's DiseaseDiane Stephenson, Derek Hill, Jesse M Cedarbaum, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 1, 2015
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 studyOsama Sabri, Marwan N Sabbagh, John Seibyl, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 4, 2021
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's DiseaseThomas Kremer, Kirsten I Taylor, Juliane Siebourg-Polster, et al.
The Lancet. Neurology|November 4, 2019
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional studyTanya Simuni, Liz Uribe, Hyunkeun Ryan Cho, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 25, 2018
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative CohortTanya Simuni, Andrew Siderowf, Shirley Lasch, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 12, 2015
Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficitsNorbert Schuff, I-Wei Wu, Shannon Buckley, et al.
Journal of Alzheimer'S Disease : JAD|November 21, 2017
Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical TrialGordon K Wilcock, Serge Gauthier, Giovanni B Frisoni, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 11, 2020
EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0Silvia Morbelli, Giuseppe Esposito, Javier Arbizu, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 17, 2020
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease ProgressionBrit Mollenhauer, Mohammed Dakna, Niels Kruse, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 17, 2024
Tau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathiesChristian Ferschmann, Konstantin Messerschmidt, Johannes Gnörich, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Journal of Parkinson'S Disease|July 16, 2019
The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's DiseaseDiane Stephenson, Derek Hill, Jesse M Cedarbaum, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 1, 2015
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 studyOsama Sabri, Marwan N Sabbagh, John Seibyl, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 4, 2021
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's DiseaseThomas Kremer, Kirsten I Taylor, Juliane Siebourg-Polster, et al.
The Lancet. Neurology|November 4, 2019
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional studyTanya Simuni, Liz Uribe, Hyunkeun Ryan Cho, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 25, 2018
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative CohortTanya Simuni, Andrew Siderowf, Shirley Lasch, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 12, 2015
Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficitsNorbert Schuff, I-Wei Wu, Shannon Buckley, et al.
Journal of Alzheimer'S Disease : JAD|November 21, 2017
Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical TrialGordon K Wilcock, Serge Gauthier, Giovanni B Frisoni, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 11, 2020
EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0Silvia Morbelli, Giuseppe Esposito, Javier Arbizu, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 17, 2020
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease ProgressionBrit Mollenhauer, Mohammed Dakna, Niels Kruse, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 17, 2024
Tau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathiesChristian Ferschmann, Konstantin Messerschmidt, Johannes Gnörich, et al.
Pageof 11